Rabeprazole and Injection site induration - a phase IV clinical study of FDA data

Summary:

Injection site induration is reported as a side effect among people who take Rabeprazole (rabeprazole sodium), especially for people who are female, 60+ old, also take Remodulin, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Injection site induration when taking Rabeprazole. It is created by eHealthMe based on reports of 31,196 people who have side effects when taking Rabeprazole from the FDA, and is updated regularly.

What is Rabeprazole?

Rabeprazole has active ingredients of rabeprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 31,689 Rabeprazole users. Check the latest studies of Rabeprazole.

What is Injection site induration?

Injection site induration is found to be associated with 554 drugs and 627 conditions by eHealthMe. Check the latest studies of Injection site induration.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

31,196 people reported to have side effects when taking Rabeprazole.
Among them, 15 people (0.05%) have Injection site induration.

Could Rabeprazole cause Injection site induration?

Among these 15 people:

What is the gender of people who have Injection site induration when taking Rabeprazole? *

female: 86.67 %
male: 13.33 %

What is the age of people who have Injection site induration when taking Rabeprazole? *

What are other drugs people take besides Rabeprazole? *

What are other side effects people have besides Injection site induration? *

Injection Site Erythema (redness at injection site): 7 people, 46.67%
Injection Site Pain: 5 people, 33.33%
Injection Site Warmth: 4 people, 26.67%
Fever: 4 people, 26.67%
Rashes (redness): 4 people, 26.67%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 26.67%
Dyspnea (difficult or laboured breathing): 3 people, 20.00%
Pneumonia: 3 people, 20.00%
Injection Site Swelling: 3 people, 20.00%
Itching: 2 people, 13.33%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 5 people, 33.33%
Hepatitis C: 2 people, 13.33%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 13.33%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 6.67%
Colon Cancer: 1 person, 6.67%
Constipation: 1 person, 6.67%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 6.67%
Depression: 1 person, 6.67%
Diabetes: 1 person, 6.67%
Gastric Disorder (disease of stomach): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Rabeprazole and have Injection site induration?

- Check whether Injection site induration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rabeprazole:

Rabeprazole (31,689 reports)

Browse all side effects of Rabeprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site induration:

Injection site induration (554 drugs)

Browse all the conditions that are associated with Injection site induration:

Injection site induration (627 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rabeprazole sodium (the active ingredients of Rabeprazole) and Rabeprazole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.